New prostate cancer combo therapy trial pulled before it even started
NCT ID NCT06765954
First seen May 11, 2026 · Last updated May 22, 2026 · Updated 4 times
Summary
This study was designed for men with high-risk prostate cancer who cannot have surgery. It planned to test three experimental drugs (N-803, ETBX-071, and M-CENK) given before and after radiation therapy. The goal was to see if the combination could eliminate cancer cells and lower PSA levels. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.